Zanidatamab
ZWI-ZW25-204
Phase 2 small_molecule completed
Quick answer
Zanidatamab for HER2-expressing Cancers is a Phase 2 program (small_molecule) at ALX ONCOLOGY HOLDINGS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALX ONCOLOGY HOLDINGS INC
- Indication
- HER2-expressing Cancers
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed